H.C. Wainwright analyst Ed Arce raised the firm’s price target on Cidara Therapeutics (CDTX) to $35 from $24 and keeps a Buy rating on the ...

H.C. Wainwright raised the firm’s price target on Solid Biosciences (SLDB) to $20 from $16 and keeps a Buy rating on the shares following the ...

HC Wainwright reaffirmed their buy rating on shares of Mind Medicine (MindMed) (NASDAQ:MNMD – Free Report) in a research ...

HC Wainwright reaffirmed their buy rating on shares of Foghorn Therapeutics (NASDAQ:FHTX – Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a $13.00 ...

Fintel reports that on March 6, 2025, HC Wainwright & Co. initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy ...

Fintel reports that on March 7, 2025, HC Wainwright & Co. initiated coverage of Surf Air Mobility (NYSE:SRFM) with a Buy ...

H.C. Wainwright analyst initiates coverage on Surf Air Mobility Inc. with a Buy rating and $12 price target, citing potential ...

H.C. Wainwright downgraded Chimerix (CMRX) to Neutral from Buy after the company agreed to be acquired for $8.55 per share in cash by Jazz Pharmaceuticals (JAZZ). The total consideration of ...

Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate ...

Plug Power (Nasdaq: PLUG). From a high north of $3, shares of the hydrogen pioneer have been cut roughly in half, falling as ...

Fintel reports that on March 5, 2025, HC Wainwright & Co. initiated coverage of Intellia Therapeutics (LSE:0JBU) with a Buy recommendation. There are 572 funds or institutions reporting positions ...

Damian Marron, interim CEO, will participate in a fireside chat moderated by Joe Pantginis, Managing Director, Equity Research at H.C. Wainwright & Co., LLC. March 27 at 08.00am EST (13.00pm CET).